Editas Medicine Inc. (EDIT)
| Bid | 1.56 |
| Market Cap | 136.03M |
| Revenue (ttm) | 32.31M |
| Net Income (ttm) | -237.09M |
| EPS (ttm) | -2.88 |
| PE Ratio (ttm) | -0.56 |
| Forward PE | -1.56 |
| Analyst | Hold |
| Ask | 1.69 |
| Volume | 949,200 |
| Avg. Volume (20D) | 3,716,639 |
| Open | 1.66 |
| Previous Close | 1.65 |
| Day's Range | 1.57 - 1.66 |
| 52-Week Range | 0.91 - 6.69 |
| Beta | 2.16 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...
Analyst Forecast
According to 15 analyst ratings, the average rating for EDIT stock is "Hold." The 12-month stock price forecast is $7, which is an increase of 330.77% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference TranscriptEditas Medicine, Inc. (NASDAQ:EDIT ) TD Cowen 45th Annual Health Care Conference March 3, 2025 2:30 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Erick Lucera - Chief Financial ...